Association between plasma proteomic dynamic changes and metabolic outcomes in patients undergoing bariatric surgery
International Journal of Obesity, 2025
Diaz-Canestro C., Yang W., Chen J., Cheung K., Han H., Wang C., Song E., Lee K., Xue J., Xu A.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Metabolic Diseases | Pathophysiology | Plasma | Olink Target 96 |
Abstract
Background
Bariatric surgery (BS) improves long-term glycemic control more effectively than medical treatment in patients with type 2 diabetes mellitus. The objective of this study was to explore the dynamic changes on inflammatory and metabolic-related circulating proteins in a large cohort of overweight patients and patients with class I to III obesity undergoing bariatric surgery (BS).
Subjects/methods
We performed quantitative proteomic analysis (399 inflammatory/metabolic proteins, Olink Proteomics) in plasma samples collected before (n = 114) and 1 month (n = 67), 3 months (n = 64), 6 months (n = 60), 12 months (n = 48) and 24 months (n = 18) after either Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).
Results
Circulating proteins primarily expressed in the liver markedly changed after BS including IGFBP-1/2 (upregulated at all time points post-surgery) and the peroxisomal enzyme HAOX1 (downregulated at all time points post-surgery). Regression analysis revealed a strong association between the changes in HAOX1 and improvements in liver enzymes. In addition, a soluble broad-spectrum pattern recognition receptor, scavenger receptor cysteine rich family member with 4 domains (SSC4D), exhibited the highest decrease among all proteins at 24 months post-surgery. Finally, we detected that inflammatory markers were transiently increased after RYGB compared to VSG as well as in patients with severe obesity compared to patients with overweight and patients with obesity at 1-month post-surgery.
Conclusions
This study identified novel inflammatory and metabolic proteins possibly implicated in the systemic metabolic response to BS.